Haemate P

Haemate P is a prescription medication that contains human coagulation factor VIII and human von Willebrand factor. It is supplied as an intravenous solution; the specific strength is not disclosed. The product is used to replace deficient clotting proteins in patients with hemophilia A or von Willebrand disease, helping to restore normal blood clotting. It is marketed in the European Union and requires administration by a healthcare professional.

Haemate P is indicated for the management of bleeding disorders that involve deficiency of factor VIII and von Willebrand factor.

- Treatment of acute bleeding episodes in patients with hemophilia A. - Routine prophylaxis to prevent spontaneous bleeds in hemophilia A. - Management of bleeding episodes in von Willebrand disease types 1, 2, and 3. - Perioperative control of hemostasis for surgical or dental procedures in affected individuals.

Adverse reactions reported with Haemate P vary in frequency and severity.

Common: - Headache. - Fever. - Nausea or vomiting. - Injection site reactions such as redness or swelling.

Serious: - Development of inhibitors (antibodies) against factor VIII. - Allergic reactions including anaphylaxis. - Thromboembolic events. - Renal dysfunction.

Clinicians should consider several precautions when prescribing Haemate P to ensure safe use.

- Assess inhibitor status before initiating therapy. - Monitor for signs of allergic reactions during and after infusion. - Use caution in patients with a history of thrombosis. - Adjust dose in individuals with renal impairment. - Avoid use in patients with known hypersensitivity to any component of the product. - Ensure proper storage conditions to maintain product stability.

Haemate P may interact with other medications that affect coagulation or immune response.

Avoid: - Concomitant use of other factor VIII concentrates without medical supervision. - Administration of pro‑thrombotic agents such as activated protein C. Use with caution: - Antifibrinolytic agents (e.g., tranexamic acid) may increase clot stability. - Immunosuppressive drugs that could alter inhibitor development. - Certain antibiotics (e.g., beta‑lactams) that may provoke hypersensitivity. - Vaccines administered shortly before or after infusion.